Twelve-week-old babies in Malawi, Thailand, and the United States are part of a groundbreaking study that could reshape how infants with HIV are treated for decades to come. In a clinical trial spanning three continents, researchers have shown for the first time that newborns can safely receive broadly neutralizing antibodies—lab-engineered proteins that target HIV—alongside standard antiretroviral therapy. This milestone, led by pediatric virologist Dr. Alka Khaitan at Indiana University School of Medicine, marks a pivotal step toward one day freeing children from lifelong HIV treatment. With 130,000 infants acquiring HIV each year and 1.5 million children already living with the virus globally, the need for alternatives to daily medication is urgent. The ultimate goal: prevent HIV from embedding itself in long-lived immune cells, where it can lie dormant for years, invisible to drugs and immune defenses.
The study focused on VRC01, a monoclonal antibody designed to block HIV’s gp120 glycoprotein—the molecular key the virus uses to unlock and enter human cells. By targeting a region of the virus that changes little across strains, broadly neutralizing antibodies (bNAbs) offer a promising way to intercept HIV early, before it establishes a permanent foothold. The trial enrolled 61 infants under 12 weeks of age, randomly assigning 30 to receive both antiretroviral therapy and subcutaneous injections of VRC01 within 14 days of treatment initiation, while 31 received antiretroviral therapy alone. The results confirmed the approach was safe and well tolerated across all sites, a critical first step in pediatric HIV research where safety thresholds are especially high.
While the addition of VRC01 did not significantly reduce HIV DNA levels after 14 weeks compared to antiretroviral therapy alone, the study provides foundational evidence that early antibody intervention is feasible. This opens the door for future trials using more potent bNAbs or combinations that may more effectively shrink the viral reservoir. As Dr. Khaitan and her international team emphasize, the rapid establishment of HIV in resting CD4 T cells is the major barrier to a cure—and intervening at the earliest stage of life may be the best chance to overcome it. The fact that infants can tolerate these antibodies so soon after birth redefines what’s possible in pediatric HIV care. With further refinement, bNAb therapy could one day help children not just manage HIV, but avoid a lifetime of treatment.